- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Kodak signs new PACS agreements
Eastman Kodak has entered into OEM deals with ISG Technologiesand Applicare Medical Imaging, continuing the Rochester, NY, company'strend toward outsourcing PACS components.In the Applicare deal, Kodak has accessed the Dutch PACS firm'sRadWorks PC-based
Eastman Kodak has entered into OEM deals with ISG Technologiesand Applicare Medical Imaging, continuing the Rochester, NY, company'strend toward outsourcing PACS components.
In the Applicare deal, Kodak has accessed the Dutch PACS firm'sRadWorks PC-based teleradiology software for marketing in 15 countriesin Europe, Africa, and the Middle East. RadWorks is a WindowsNT-based product that can be linked to Kodak's Digital Sciencemedical image management software. Kodak's Australian subsidiaryalso received rights to market RadWorks in Australia and New Zealand,alongside Applicare's existing distributor in the region, OxfordScientific.
Details on the agreement with ISG of Mississauga, Ontario, aresketchy, but ISG president Thomas Cafarella confirmed that hiscompany has entered a deal with Kodak Health Imaging divisionin Richardson, TX, to supply Kodak with distributed viewing softwarefor use in PACS applications. Kodak signed a deal with ISG competitorCemax-Icon earlier this year (SCAN 2/28/96).
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
